المؤلفون: Ríos-Tamayo, Rafael, Soler, Juan Alfons, García-Sánchez, Ricarda, Pérez Persona, Ernesto, Arnao, Mario, García-Guiñón, Antoni, Domingo, Abel, González-Pardo, Miriam, de la Rubia Comos, Javier, Mateos, Maria-Victoria, GeminiS Study Investigators

مصطلحات موضوعية: Relapsed-refractory multiple myeloma, Real-world, Monoclonal antibodies, Daratumumab, Standard of care, 32 Ciencias Médicas

الوصف: The aim of this study is to describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives. ; This study was sponsored by Janssen-Cilag. Janssen-Cilag participated in the study design, data analysis and drafting of the manuscript. All investigators received financial com- pensation for their participation in the study. ; Medicina

العلاقة: http://hdl.handle.net/20.500.12466/4403Test

الإتاحة: https://doi.org/20.500.12466/440310.1080/16078454.2023.2178997Test
https://hdl.handle.net/20.500.12466/4403Test

المؤلفون: Hernández-Rivas, José-Ángel, Arnao, Mario, Arguiñano Pérez, José Maria, Rubio, Araceli, García, Esther Gónzalez, de Miguel, Dunia, Cherepanov, Dasha, Romanus, Dorothy, Verleger, Katharina, Johnson, Courtney, Corman, Shelby L, Grande, Marta, Persona, Ernesto Pérez

المساهمون: Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

المصدر: Future Oncology ; volume 17, issue 26, page 3465-3476 ; ISSN 1479-6694 1744-8301

الإتاحة: https://doi.org/10.2217/fon-2021-0301Test

المؤلفون: Puig, Noemi, Hernández, Miguel T, Rosiñol, Laura, González, Esther, de Arriba, Felipe, Oriol, Albert, González-Calle, Verónica, Escalante, Fernando, de la Rubia, Javier, Gironella, Mercedes, Ríos, Rafael, García-Sánchez, Ricarda, Arguiñano, José M, Alegre, Adrián, Martín, Jesús, Gutiérrez, Norma C, Calasanz, María J, Martín, María L, Couto, María Del Carmen, Casanova, María, Arnao, Mario, Pérez-Persona, Ernesto, Garzón, Sebastián, González, Marta S, Martín-Sánchez, Guillermo, Ocio, Enrique M, Coleman, Morton, Encinas, Cristina, Vale, Ana M, Teruel, Ana I, Cortés-Rodríguez, María, Paiva, Bruno, Cedena, M Teresa, San-Miguel, Jesús F, Lahuerta, Juan J, Bladé, Joan, Niesvizky, Ruben, Mateos, María-Victoria

مصطلحات موضوعية: Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Clarithromycin, Dexamethasone, Female, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Male, Multiple Myeloma, Transplantation, Autologous, Treatment Outcome

الوصف: Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 patients with MM ineligible for ASCT received Rd with or without clarithromycin until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). With a median follow-up of 19 months (range, 0-54), no significant differences in the median PFS were observed between the two arms (C-Rd 23 months, Rd 29 months; HR 0.783, p = 0.14), despite a higher rate of complete response (CR) or better in the C-Rd group (22.6% vs 14.4%, p = 0.048). The most common G3-4 adverse events were neutropenia [12% vs 19%] and infections [30% vs 25%], similar between the two arms; however, the percentage of toxic deaths was higher in the C-Rd group (36/50 [72%] vs 22/40 [55%], p = 0.09). The addition of clarithromycin to Rd in untreated transplant ineligible MM patients does not improve PFS despite increasing the ≥CR rate due to the higher number of toxic deaths in the C-Rd arm. Side effects related to overexposure to steroids due to its delayed clearance induced by clarithromycin in this elderly population could explain these results. The trial was registered in clinicaltrials.gov with the name GEM-CLARIDEX: Ld vs BiRd and with the following identifier NCT02575144. The full trial protocol can be accessed from ClinicalTrials.gov. This study received financial support from BMS/Celgene.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/17818Test; PMC8139975; https://www.nature.com/articles/s41408-021-00490-8.pdfTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139975/pdfTest

الإتاحة: https://doi.org/10.1038/s41408-021-00490-8Test
http://hdl.handle.net/10668/17818Test
https://www.nature.com/articles/s41408-021-00490-8.pdfTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139975/pdfTest

المؤلفون: Romero, Samuel, Balaguer-Roselló, Aitana, Montoro, Juan, Beneit, Paola, Martínez, Amelia, Ruiz, Cristina, Andreu, Rafael, Guerreiro, Manuel, Arnao, Mario, Montava, Alberto, Vicente, Ana I., Jarque, Isidro, Sanz, Jaime

المصدر: Therapeutic Advances in Hematology ; volume 12, page 204062072110381 ; ISSN 2040-6207 2040-6215

مصطلحات موضوعية: Hematology

الوصف: The poor prognosis of refractory or relapsed (R/R) classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation has improved greatly due to the introduction of brentuximab vedotin and PD-1 inhibitors. However, the duration of response achieved with these novel agents is too short. The information about the management of patients after anti-PD-1 therapy failure is very limited in cHL, although chemotherapy alone or combined with PD-1 inhibitors has shown encouraging results. We report three cases of heavily pretreated cHL, refractory to nivolumab monotherapy, successfully rescued with the addition of chemotherapy to nivolumab, as a bridge to allogeneic stem cell transplantation (allo-SCT). All three patients presented poor clinical features such as three to four previous lines including brentuximab vedotin and autologous stem cell transplantation, refractoriness to the last line of therapy previous to nivolumab, and rapid disease progression. Notwithstanding these characteristics and nivolumab failure, they achieved a complete response after the addition of chemotherapy, were consolidated with allo-SCT, and still remain in complete response. There are few studies concerning the combination of PD-1 inhibitors and chemotherapy after nivolumab failure, including one retrospective study and one phase II trial with nivolumab plus bendamustine. Therefore, only few patients are consolidated with allo-SCT. However, there are several ongoing trials investigating new combinations of chemotherapy and PD-1 inhibitors in R/R cHL, as well as in first line. All these data suggest that anti-PD-1 therapy may reprogram the immune system, activating and inhibiting effector and immunosuppressive cells, respectively, leading to overtake of chemorefractoriness. Allo-SCT can increase the immune-related events of patients treated with anti-PD-1 previously, consistent on acute graft- versus-host disease, sinusoidal obstruction syndrome, and noninfectious febrile syndrome. In conclusion, the combination of PD-1 inhibitor ...

الإتاحة: https://doi.org/10.1177/20406207211038181Test

المؤلفون: Sanz, Jaime, Moscardó, Federico, Montoro, Juan, Cano, Isabel, Guerreiro, Manuel, Dasí, María A., Solves, Pilar, Lorenzo, Ignacio, Gómez-Segui, Inés, Montesinos, Pau, Mora, Elvira, Arnao, Mario, Sempere, Amparo, Jarque, Isidro, Carretero, Carlos, Senent, Leonor, Vicente, Ana, Andreu, Rafael, Luna, Irene, Balaguer-Roselló, Aitana, Carpio, Nelly, Sanz, Guillermo F., Sanz, Miguel A., Piñana, José L.

المصدر: Biology of Blood and Marrow Transplantation ; volume 26, issue 1, page 83-87 ; ISSN 1083-8791

مصطلحات موضوعية: Transplantation, Hematology

الإتاحة: https://doi.org/10.1016/j.bbmt.2019.08.020Test
https://api.elsevier.com/content/article/PII:S1083879119305609?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1083879119305609?httpAccept=text/plainTest

المؤلفون: de la Rubia, Javier, Garcia-Ruiz, Cristian, Álvaro, Diaz-Gonzalez, Vicente, Ana, Arnao, Mario, Cortti, María José, Romero, Alberto, Escola, M. Ángeles, Such, Esperanza

المصدر: Clinical Lymphoma Myeloma and Leukemia ; volume 23, page S227 ; ISSN 2152-2650

مصطلحات موضوعية: Cancer Research, Oncology, Hematology

الإتاحة: https://doi.org/10.1016/s2152-2650Test(23)01959-6
https://api.elsevier.com/content/article/PII:S2152265023019596?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2152265023019596?httpAccept=text/plainTest

المؤلفون: de la Rubia, Javier, Montoro, Juan, Sanz, Jaime, Balaguer, Aitana, Guerreiro, Manuel, Facal, Ana, Villalba, Marta, Chorao, Pedro, Arnao, Mario, Louro, Alberto, Sanz, Miguel

المصدر: Clinical Lymphoma Myeloma and Leukemia ; volume 23, page S169-S170 ; ISSN 2152-2650

مصطلحات موضوعية: Cancer Research, Oncology, Hematology

الإتاحة: https://doi.org/10.1016/s2152-2650Test(23)01861-x
https://api.elsevier.com/content/article/PII:S215226502301861X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S215226502301861X?httpAccept=text/plainTest

المؤلفون: Villalba, Ana, Gonzalez-Rodriguez, Ana Pilar, Arzuaga-Mendez, Javier, Puig, Noemí, Arnao, Mario, Arguiñano, José María, Jimenez, María, Canet, Marta, Teruel, Ana I., Sola, María, Díaz, Francisco J., Encinas, Cristina, Garcia, Antonio, Rosiñol, Laura, Suárez, Alexia, Gonzalez, Marta Sonia, Izquierdo, Isabel, Hernández, Miguel Teodoro, Infante, María Stefania, Sánchez, María José, Sampol, Antonia, de la Rubia, Javier

المصدر: Leukemia & Lymphoma ; volume 63, issue 14, page 3438-3447 ; ISSN 1042-8194 1029-2403

الإتاحة: https://doi.org/10.1080/10428194.2022.2123229Test

المؤلفون: Villalba, Ana, Lloret, Pilar, Rodríguez, Ana Pilar González, Arzuaga-Méndez, Javier, Puig, Noemí, Arnao, Mario, Arguiñano, José María, Jiménez, María, Canet, Marta, Teruel, Ana I., Sola, María, Díaz, Francisco J., Encinas, Cristina, García, Antonio, Rosiñol, Laura, Suárez, Alexia, González, Marta Sonia, Izquierdo, Isabel, Hernández, Miguel Teodoro, Infante, María Stefania, Sánchez, María José, Sampol, Antonia, De la Rubia, Javier

المصدر: Clinical Lymphoma Myeloma and Leukemia ; volume 22, page S158 ; ISSN 2152-2650

مصطلحات موضوعية: Cancer Research, Oncology, Hematology

الإتاحة: https://doi.org/10.1016/s2152-2650Test(22)00554-7
https://api.elsevier.com/content/article/PII:S2152265022005547?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2152265022005547?httpAccept=text/plainTest

المؤلفون: Rodriguez-Otero, Paula, Sirvent, Maialen, González-Rodríguez, Ana Pilar, Lavilla, Esperanza, de Coca, Alfonso García, Arguiñano, José María, Martí, Josep M., Cabañas, Valentin, Motlló, Cristina, de Cabo, Erik, Encinas, Cristina, Murillo, Ilda, Hernández-Rivas, Jose Ángel, Pérez-Persona, Ernesto, Casado, Felipe, Sampol, Antonia, García, Ricarda, Blanchard, María Jesús, Anguita, Magdalena, Lafuente, Ana Paz, Iñigo, Belén, López, Aurelio, Ribas, Paz, Arnao, Mario, Maldonado, Roberto, Bladé, Joan, Mateos, María Victoria, Lahuerta, Juan José, San Miguel, Jesús F.

المصدر: Clinical Lymphoma Myeloma and Leukemia ; volume 21, issue 6, page 413-420 ; ISSN 2152-2650

مصطلحات موضوعية: Cancer Research, Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.clml.2021.02.004Test
https://api.elsevier.com/content/article/PII:S2152265021000653?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2152265021000653?httpAccept=text/plainTest